HCM
NVCT icon

Hollencrest Capital Management’s Nuvectis Pharma NVCT Stock Holding History

Hollencrest Capital Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-400
Closed -$2.16K – 1206
2024
Q4 		$2.16K Buy
400
+120
+43% +$752 ﹤0.01% 1004
2024
Q3 		$1.76K Hold
280
– – ﹤0.01% 971
2024
Q2 		$1.77K Hold
280
– – ﹤0.01% 943
2024
Q1 		$2.3K Hold
280
– – ﹤0.01% 886
2023
Q4 		$2.33K Hold
280
– – ﹤0.01% 874
2023
Q3 		$3.61K Sell
280
-2,760
-91% -$40K ﹤0.01% 857
2023
Q2 		$48.5K Buy
+3,040
New +$48.5K 0.01% 498

Other funds holding NVCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

Hollencrest Capital Management's NVCT Position: Q1 2025 in Review

Hollencrest Capital Management sold out of Nuvectis Pharma (NVCT) in Q1 2025, closing a stake of 400 shares — an estimated $2.16K sold.

Hollencrest Capital Management first reported a position in NVCT in Q2 2023 and held it in 7 quarters. The position peaked at $48.5K in Q2 2023. 33 funds tracked by Wall St. Rank hold NVCT as of Q1 2025.

  • Hollencrest Capital Management reported no remaining Nuvectis Pharma position as of Q1 2025 after selling out during the quarter.
  • Hollencrest Capital Management sold 400 Nuvectis Pharma shares in Q1 2025, an estimated $2.16K.
  • Hollencrest Capital Management first reported a position in Nuvectis Pharma in Q2 2023 and held it in 7 quarters.
  • Hollencrest Capital Management's Nuvectis Pharma position peaked at $48.5K in Q2 2023.
  • 33 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2025.

Based on Hollencrest Capital Management's 13F filing for Q1 2025, filed 5 May 2025.